Share
Hormone replacement therapy and heart health… what comes to mind?
Is your knee-jerk reaction that it’s not safe?
There are a myriad of studies spanning decades regarding hormone replacement therapy (HRT) and cardiovascular disease, with conflicting results that led many women to believe HRT was “bad.” Now that the FDA has retracted the black box warnings about risks of stroke, heart attack, breast cancer, and dementia, it’s time to reopen that discussion.
There is a lot of information here, ladies, so hold onto your hats. We’re covering some ground.
Why did doctors originally think hormone therapy protected the heart?
Before the early 2000s, many clinicians believed estrogen offered cardiovascular protection.
That assumption wasn’t baseless. Observational studies showed that premenopausal women had lower rates of cardiovascular disease than men of the same age. The difference? Estrogen, and researchers suspected it played a protective role.
Premenopausal estrogen levels positively influence blood vessel function, lipid metabolism, and inflammatory signaling. It encourages the production of nitric oxide, a molecule that relaxes blood vessels and supports healthy circulation. It can also reduce levels of certain atherogenic lipoproteins (which promote plaque buildup in the arteries) while improving insulin sensitivity in some women.
Taken together, these observations helped build the belief that hormone therapy might not only relieve menopausal symptoms but also help prevent cardiovascular disease.
Then a major clinical trial changed everything.
Didn’t a major study show that hormone therapy was dangerous?
Yes – and for many years, that study shaped public perception.
The Women’s Health Initiative (WHI) trial, launched in 1993, was the largest randomized trial ever conducted on hormone therapy. More than 27,000 postmenopausal women between the ages of 50 and 79 were enrolled and placed into two main treatment groups: women receiving estrogen combined with progestin and women receiving estrogen alone.
In 2002, the trial was stopped early after researchers observed higher rates of invasive breast cancer, stroke, pulmonary embolism, and coronary heart disease in the treatment group compared with the placebo. It generated massive headlines and led to a dramatic drop in hormone therapy prescriptions almost overnight.
However, the study population was not representative of the women most likely to start therapy in the real world. Most of the study participants were well past menopause, and some already had underlying cardiovascular disease. It later became clear that these factors may have influenced the results far more than initially appreciated. The story was more complicated than the headlines suggested.
Why did the WHI results cause so much confusion, and what changed in our understanding?
The biggest shift came when researchers began analyzing the results by age and time since menopause, rather than treating all participants as one group. One key issue was who was actually enrolled in the trial.
When the data were stratified this way, a very different pattern emerged.
Women who started hormone therapy between the ages of 50 and 59, or within roughly ten years of menopause, tended to have much more favorable cardiovascular outcomes than older participants. Some analyses even suggested a reduction in coronary heart disease risk among these younger women.
Meanwhile, women who began therapy two decades after menopause or in their 70s showed increased cardiovascular risk. Many participants were well past menopause when they started hormone therapy, some by 15 or even 20 years. Others already had underlying cardiovascular disease.
This raised an important question: were the observed risks caused by hormone therapy itself, or by introducing hormones into an already diseased cardiovascular system?
This realization led to a new framework for understanding hormone therapy: the timing hypothesis, sometimes referred to as the “window of opportunity.” As researchers began analyzing the data by age and time since menopause, a striking pattern appeared.
What is the “timing hypothesis,” and why did it change the conversation?
The timing hypothesis proposes that hormone therapy interacts differently with the cardiovascular system depending on the state of the arteries when treatment begins relative to menopause.
Women who initiate therapy before age 60 or within about 10 years of menopause appear to experience very different cardiovascular outcomes than women who begin therapy decades later.
In younger postmenopausal women, blood vessels are generally still relatively healthy. In that environment, estrogen can enhance endothelial function, stimulate nitric oxide production, and help maintain vascular flexibility.
But arteries change with time, and atherosclerotic plaques gradually accumulate within the vessel walls as we age. Introducing estrogen into an advanced disease environment where atherosclerosis has developed can provoke inflammatory activity or destabilize endothelial function. This raises the likelihood of clot formation and cardiovascular complications.
In simple terms, estrogen helps maintain vascular health before significant disease develops, but its effects are less predictable once atherosclerosis is established. This shift in understanding reframed hormone therapy not as universally harmful or beneficial, but as highly dependent on timing and vascular health.
What evidence supports the timing hypothesis?
Several studies have directly explored this concept.
The Early vs. Late Intervention Trial with Estradiol (ELITE) compared women who began estrogen therapy shortly after menopause with those who started more than a decade later. Researchers tracked the progression of carotid artery thickening, a marker of atherosclerosis. Over the course of the study, women who initiated therapy within six years of menopause experienced significantly slower arterial thickening than those who started later.¹
Another study, the Danish Osteoporosis Prevention Study (DOPS), followed recently menopausal women for more than 16 years. Participants who received hormone therapy close to the onset of menopause demonstrated lower rates of heart attack, heart failure, and overall mortality compared with those who did not receive treatment.¹
Together, these findings reinforce the idea that timing, specifically early versus late initiation, can produce very different cardiovascular effects and outcomes.
Why does menopause itself increase cardiovascular risk?
Menopause is a major endocrine transition that affects multiple physiological systems. That’s a fact.
As ovarian function declines, estrogen levels drop, and follicle-stimulating hormone (FSH) rises, and the fluctuation does more than end menstrual cycles. The resulting hormonal changes influence vascular biology, metabolism, and inflammatory signaling.
One of the earliest changes occurs in the endothelium, the thin layer of cells lining blood vessels. Estrogen normally supports endothelial health by stimulating production of nitric oxide and regulating vascular tone. When estrogen levels decline, endothelial function can deteriorate.
At the same time, metabolic changes oftentimes emerge. Lipid profiles shift, insulin sensitivity can decline, and inflammatory signaling can increase. Together, these changes contribute to the gradual rise in cardiovascular risk after menopause.
Are menopausal symptoms, like hot flashes and night sweats, linked to cardiovascular health?
Interestingly, they may be.
Vasomotor symptoms (the hot flashes and night sweats) are the most common reason women seek hormone therapy and are often viewed as uncomfortable but harmless features of menopause.
But research suggests these symptoms may be more than temperature regulation and reflect bigger physiological changes.¹
Women experiencing frequent or severe vasomotor symptoms may be demonstrating signs of vascular instability, including fluctuations in blood vessel responsiveness and autonomic nervous system activity. It’s linked with markers of endothelial dysfunction, suggesting that the severity of menopausal symptoms may correlate with cardiovascular risk later in life.
Are all hormone therapies the same?
Not even close – and this is one of the most important developments in the field.
Many early trials evaluated conventional hormone therapy regimens, particularly conjugated equine estrogens combined with synthetic progestins such as medroxyprogesterone acetate.
Modern hormone therapy has evolved significantly and is far more individualized. Clinicians now often use:
- bioidentical estradiol, which closely resembles the estrogen produced by the human body
- micronized progesterone, a form of progesterone with a more favorable metabolic profile
- lower hormone doses than those used in earlier trials
- alternative delivery routes such as transdermal patches or gels
These changes can influence how hormones interact with the body and may affect cardiovascular and thrombotic (clotting) risk.
Why does the route of hormone delivery matter?
The route of administration affects how hormones are metabolized, and that influences their physiological effects.
Oral estrogen passes through the liver before reaching systemic circulation. This “first-pass” effect stimulates the liver to produce clotting factors and other inflammatory proteins, which may partially explain the increased risk of venous thromboembolism observed with oral formulations.
Transdermal estrogen (patches or topical preparations) bypasses the liver and enters the bloodstream directly. Because of this, it appears to have less impact on clotting pathways and may carry a lower risk of blood clots in many patients.
This distinction has become an important consideration when selecting therapy for women with elevated cardiovascular or thrombotic risk. For this population, clinicians increasingly favor transdermal options.
The black box warnings have been removed, so why is careful screening still necessary before starting hormone therapy?
Even with improved understanding of hormone therapy, it is not appropriate for everyone. Hormone therapy still requires careful risk assessment.
Before initiating treatment, clinicians typically evaluate:
- blood pressure
- lipid levels
- diabetes risk
- smoking status
- family history of cardiovascular disease
- personal history of blood clots or stroke
For example, oral estrogen has been associated with approximately a twofold increase in venous thromboembolism risk in certain populations, particularly during the first year of therapy. Although the absolute risk remains relatively low in younger women, it increases with age and underlying health conditions.
Stroke risk also appears to vary by dose and formulation, with lower-dose and transdermal regimens generally showing more favorable safety profiles.
A thorough assessment helps determine whether hormone therapy is a reasonable option and which formulation may be safest.
What about women who already have heart disease?
This is where caution becomes particularly important.
The Heart and Estrogen/Progestin Replacement Study (HERS) specifically examined whether hormone therapy could prevent recurrent coronary events in women with existing heart disease.¹
The results were not encouraging. Hormone therapy did not reduce overall cardiovascular events in postmenopausal women with cardiovascular conditions, and the first year of treatment was associated with an increased rate of coronary complications.
Follow-up studies confirmed that hormone therapy should not be started for the purpose of preventing additional heart events in women who already have coronary disease.
What about women with a history of pre-eclampsia?
This is an especially important but often overlooked group.
Women who experienced pre-eclampsia during pregnancy face a significantly higher lifetime risk of cardiovascular disease. Studies suggest they are three to four times more likely to develop chronic hypertension and ischemic heart disease later in life.¹
Because pre-eclampsia is associated with vascular dysfunction, the timing hypothesis is particularly relevant for these women. Early initiation of hormone therapy during menopause could potentially help preserve endothelial function that was previously impaired during pregnancy.
For these patients, transdermal estrogen is often preferred because it avoids the hepatic first-pass effect and has less impact on blood pressure and clotting pathways.
What do current medical guidelines recommend?
Major menopause societies emphasize a personalized approach to hormone therapy rather than generalized or blanket recommendations.
For women who are younger than 60 or within about 10 years of menopause and experiencing significant symptoms, the benefits of hormone therapy often outweigh the risks when no contraindications are present, and when appropriate screening and monitoring are performed.
Experts generally advise against starting hormone therapy solely to prevent cardiovascular disease, particularly in women many years past menopause. Treatment should consider each woman’s overall cardiovascular risk profile, symptom burden, and personal preferences before making treatment decisions.
Why is careful medical oversight still important?
Despite decades of research and a better understanding of hormone therapy, uncertainties persist.
Past clinical trials have varied widely in their design, patient populations, dosing strategies, and hormone formulations. Many studies also lack long-term follow-up data for newer therapies. In addition, some populations, including racial and ethnic minorities, have been underrepresented in clinical studies. For instance, we know that menopause tends to begin earlier in black women and that they experience a longer, more severe menopausal transition than white women. This, in turn, impacts the timing and effects of hormone therapies. But many studies in the past do not reflect these differences.
Researchers are currently exploring whether genetics, metabolic differences, and social determinants of health influence how women respond to hormone therapy. For example, variations in estrogen receptor genes or metabolic enzymes may affect cardiovascular outcomes. Future studies may help identify which patients are most likely to benefit and which may face higher risks.
A thorough discussion with your physician regarding your medical and familial history, as well as routine follow-ups, can help initiate therapy and guide future decision-making.
So, where does that leave us today?
The relationship between hormone therapy and heart health is far more complex than early headlines suggested.
Over the past two decades, researchers have learned that timing, formulation, dose, and patient characteristics all influence cardiovascular outcomes.
What’s the verdict on safety? For many women navigating menopause, hormone therapy remains one of the most effective tools for symptom relief. And when used thoughtfully in the right patients, modern approaches provide a more favorable cardiovascular profile than earlier research once implied.
As decades of evolving science have shown, the key is not simply whether hormone therapy is used – but how, when, and for whom. Hormone therapy is not a universal solution, and its use should always be guided by thoughtful clinical evaluation and shared decision-making.
At Aayla, we’re dedicated to supporting women who have too often felt overlooked or resigned to living with sexual and intimate health challenges. No woman should feel alone or unheard in her struggles. Our mission is to provide compassionate, personalized care that meets women where they are – helping them reclaim confidence, comfort, and connection in their lives.
If you have questions about menopause or your overall sexual health, reach out to our team of women who get it!
Reference:
- Khalifey, H. T., Mahereen, R., Adwan, R., Chahine, R., Kaidali, M., Mirza, S. F., Tullah, S. N., Shaikh, S., Hammad, S., & Sukkarieh, H. H. (2026). The impact of hormone replacement therapy on cardiovascular health in postmenopausal women: a narrative review. Frontiers in reproductive health, 8, 1745210. https://doi.org/10.3389/frph.2026.1745210.